Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Pancreatic Neoplasms 2Locally Advanced Rectal Cancer 2Colonic Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Cancer Patients 1Non-squamous Non-small-cell Lung Cancer 1Mouth Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamour Cell Cancer 1Endometrioid Endometrial Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Primary Liver Cancer 1

Interventions

Gemcitabine 3Cisplatin 2durvalumab 1camrelizumab 1apatinib 1Tegafur 1Surgical Procedures, Operative 1Simvastatin 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Biliary Tract Carcinoma × camrelizumab × 1 year × Clear all
NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Advanced Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡